LANDOGROZUMAB
UNII B1792M902R

Substance Identification & Data

This profile provides standardized clinical and technical data for Landogrozumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) B1792M902R.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1391726-30-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

B1792M902R

CAS Registry Number

1391726-30-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LANDOGROZUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C99640

National Cancer Institute reference terminology for clinical and research data.

INN ID

10188

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

BC-01

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Landogrozumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LANDOGROZUMAB

Common Names & Synonyms

ANTI-MYOSTATIN ANTIBODY

IMMUNOGLOBULIN, ANTI-(HUMAN GROWTH DIFFERENTIATION FACTOR 8) (HUMAN-MUS MUSCULUS MONOCLONAL LY2495655 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL LY2495655 .KAPPA.-CHAIN, DIMER

LANDOGROZUMAB [INN]

LANDOGROZUMAB [USAN]

LANDOGROZUMAB [WHO-DD]